삼성제약

001360KOSPI

54.4 / 100

Reference Date: 2026-09-08

Financial Score23.0 / 40

News Sentiment14.4 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly up 1.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Pharmaceutical operates in pharmaceutical manufacturing and sales, biopharma, and health food sectors, distributing a wide range of products including specialty and over-the-counter drugs. The company is advancing clinical trials for pancreatic cancer treatment GV1001 and Alzheimer's disease, with revenue reaching 460.7 billion KRW in 2025.

Number of Employees

87people

Average Salary

66.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.76Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

1.03Industry Average 1.204.0Point

In line with industry avg

ROE

10.18Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

3.37Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼5.4% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼2.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -10.9% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 1Average Sentiment Score 57.5

Neutral
롯데건설, ‘화성 향남 롯데캐슬 시그니처’ 10월 분양 예정
롯데건설의 새로운 아파트 분양 계획이 발표되었으나, 삼성제약과 직접적인 연관성이 없다.
Negative
삼성제약 CB 1년 만에 75% 되사기…주가 부진 '나비효과'
삼성제약의 CB 대규모 상환으로 인해 주가 부진이 지속되며 투자자 신뢰도 하락.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 1,324Won52-week high 2,21052-week low 1,180

1-month return3.0Point

1m 1.69% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주요사항보고서(전환사채권발행결정)2026-09-02
Neutral주식등의대량보유상황보고서(약식)2026-08-25
Neutral반기보고서 (2026.06)2026-08-14
Neutral주요사항보고서(자기전환사채만기전취득결정)2026-08-12